According to our recent payer coverage analysis for chronic idiopathic constipation treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access for chronic idiopathic constipation treatments shows that under the pharmacy benefit, about 41% of the lives under commercial formularies are covered with utilization management restrictions.
Trends: In March 2020, the FDA approved Sebela Pharmaceuticals’ Pizensy (lactitol) for oral solution for the treatment of chronic idiopathic constipation in adults. Unlike solid oral treatments, the medication can be mixed with the patient’s fluid of choice, including water, juice, coffee, tea and soda.